Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Type I diabetes mellitus | R-HSA-5683209 | map04940 | tyloxapol | 5281416 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | tyloxapol | 5281416 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | tyloxapol | 5281416 | drug-path |
Calcium signaling pathway | R-HSA-381753 | map04020 | tyloxapol | 5281416 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | metyrapone | 4174 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | metyrapone | 4174 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | metyrapone | 4174 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | metyrapone | 4174 | drug-path |
Axon guidance | R-HSA-422475 | map04360 | metyrapone | 4174 | drug-path |
p53 signaling pathway | R-HSA-168638 | map04115 | metyrapone | 4174 | drug-path |
Asthma | R-HSA-444620 | map05310 | metyrapone | 4174 | drug-path |
Chemokine signaling pathway | R-HSA-168638 | map04062 | metyrapone | 4174 | drug-path |
Allograft rejection | R-HSA-9679028 | map05330 | metyrapone | 4174 | drug-path |
Type I diabetes mellitus | R-HSA-5683209 | map04940 | metyrapone | 4174 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | metyrapone | 4174 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | valinomycin | 3000706 | drug-path |
Alzheimer's disease | R-HSA-1643685 | 0 | valinomycin | 3000706 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | valinomycin | 3000706 | drug-path |
Huntington's disease | R-HSA-1643685 | 0 | valinomycin | 3000706 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | valinomycin | 3000706 | drug-path |